Advitech announces new efficacy results for Dermylex and compliance with FDA regulations on claims
Advitech Inc. announced that a post-marketing study conducted on patients suffering from psoriasis shows that the use of Dermylex(TM) may benefit patients already using topical corticosteroids. Using Dermylex(TM) with topical corticosteroids may create a synergistic effect and improve overall treatment efficacy results. Therefore, Dermylex(TM) might act as an adjuvant to topical corticosteroids.
"This new data provides Advitech and its commercial partners with important information on treatment strategies and alternatives. Adding Dermylex(TM) to a topical corticosteroid treatment appears to reduce psoriasis severity," stated Dr. Christina Juneau, Advitech's Vice-President of Research and Development. "Advitech will continue to gather and monitor additional data and results from this post-marketing study in order to develop therapeutic strategies for Dermylex(TM) users."
These observations arise from a study by Advitech in which Dermylex(TM) users were invited to provide their own evaluation and comment on the results obtained with Dermylex(TM) whether taken alone or part of a concomitant treatment for psoriasis. In the questionnaire, psoriasis severity was quantified by means of an intensity scale.
Other news from the department research and development
